Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)

PATRIK PALACKA, JAN SLOPOVSKY, JANA OBERTOVA, MICHAL CHOVANEC, KATARINA REJLEKOVA, ZUZANA SYCOVA-MILA, BORIS KOLLARIK, JOZEF MARDIAK and MICHAL MEGO
Anticancer Research November 2021, 41 (11) 5749-5759; DOI: https://doi.org/10.21873/anticanres.15391
PATRIK PALACKA
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pal_patrick@yahoo.co.uk
JAN SLOPOVSKY
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JANA OBERTOVA
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAL CHOVANEC
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATARINA REJLEKOVA
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZUZANA SYCOVA-MILA
2National Cancer Institute, Bratislava, Slovak Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BORIS KOLLARIK
3Department of Urology, University Hospital in Bratislava, Bratislava, Slovak Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOZEF MARDIAK
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAL MEGO
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Systemic immune-inflammation index (SII) predicts survival of patients with various malignancies. This study explored the prognostic value of SII in metastatic urothelial carcinoma (MUC) subjects. Patients and Methods: We evaluated 181 consecutive MUC patients treated with first-line platinum-based therapy. Karnofsky performance status <80% and visceral metastasis were present in 18.2% and 46.4% of patients, respectively. SII was based on platelet × neutrophil/lymphocyte counts. Study population was dichotomized by median into high and low SII groups before the initiation of chemotherapy and at week 6. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan–Meier method and compared with the log-rank test. Results: At median follow-up of 9.6 months, 174 patients experienced disease progression and 173 died. Patients with low SII at baseline and at week 6 had significantly better PFS (HR=0.58; p=0.0002 and HR=0.55; p<0.0001) and OS (HR=0.54; p<0.0001 and HR=0.54; p<0.0001) compared to patients with high SII. Independent prognostic value of SII was confirmed in a multivariate analysis. Conclusion: High SII before chemotherapy that persists at week 6 negatively affects survival. SII at baseline can be used in the stratification of patients within clinical trials and in clinical practice.

Key Words:
  • Systemic immune-inflammation index
  • metastatic urothelial carcinoma
  • platinum-based chemotherapy
  • survival
  • response to treatment
  • Received September 20, 2021.
  • Revision received October 10, 2021.
  • Accepted October 12, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (11)
Anticancer Research
Vol. 41, Issue 11
November 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)
PATRIK PALACKA, JAN SLOPOVSKY, JANA OBERTOVA, MICHAL CHOVANEC, KATARINA REJLEKOVA, ZUZANA SYCOVA-MILA, BORIS KOLLARIK, JOZEF MARDIAK, MICHAL MEGO
Anticancer Research Nov 2021, 41 (11) 5749-5759; DOI: 10.21873/anticanres.15391

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)
PATRIK PALACKA, JAN SLOPOVSKY, JANA OBERTOVA, MICHAL CHOVANEC, KATARINA REJLEKOVA, ZUZANA SYCOVA-MILA, BORIS KOLLARIK, JOZEF MARDIAK, MICHAL MEGO
Anticancer Research Nov 2021, 41 (11) 5749-5759; DOI: 10.21873/anticanres.15391
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment
  • Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
  • Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • systemic immune-inflammation index
  • metastatic urothelial carcinoma
  • platinum-based chemotherapy
  • survival
  • response to treatment
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire